Although aberrant expression of cytokines such as IL-1B and IFNG in blood from psychiatric patients supports a role of inflammation in the pathogenesis of the disease, little is known about mechanisms underlying their regulation. We aimed to evaluate the putative role of IFNG-AS1 long non-coding RNA (lncRNA) in controlling of IFNG locus in patients with schizophrenia (SZ) and bipolar (BP). We analysed the expression levels of IFNG-AS1 long non-coding RNA, and IFNG and IL-1B mRNAs in blood cells from 27 SZ-and 30 BPmedicated patients and in 32 healthy controls. Our data showed that IFNG-AS1 expression dramatically decreased in BP and SZ patients compared with controls and was significantly correlated with IFNG expression in patients specifically. Transcript levels of IL-1B were also significantly reduced in BP and SZ patients compared with controls. No significant differences in the expression of IFNG-AS1, IFNG and IL-1B genes were found between patients with BP and SZ. Our data shed further light on the potential role of inflammation, and more particularly inflammatory lncRNAs, in SZ and BP diseases and their pharmacological treatment.
Introduction
Schizophrenia (SZ) and bipolar (BP) disorders are clinically and aetiologically heterogeneous debilitating chronic psychiatric diseases. Several studies have revealed that both genetics and environmental factors are involved in the pathogenesis of SZ and BP [1] . Despite marked differences in the aetiology and clinical course between BP and SZ diseases, they share common features regarding underlying genetic loci and gene expression changes [2, 3] . Inflammation and infections have been implicated in the pathogenesis of SZ [4] and BP [5] , and dysregulated levels of inflammatory molecules and cytokines were found in peripheral blood from patients with SZ and BP [6] . IL-1b is a pro-inflammatory cytokine secreted by a variety of cells such as peripheral and brain macrophages (monocytes, microglial cells), astrocytes and brain endothelial cells and is a known proinflammatory mediator of inflammatory reactions of the central nervous system (CNS) [7] . IL-1b involvement in the pathogenesis of psychiatric disease such as SZ and BP likely arises from its effect on the development of the neurotransmitter systems [8, 9] and its contribution to neuroimmune and neuroinflammatory processes, the latter via activation of other immune cells such as peripheral and CNS-resident macrophages and T cells, disruption of the blood-brain barrier (BBB) and subsequent alteration of the brain functions [10, 11] . Another important inflammatory mediator, which was found dysregulated in SZ and BP [12, 13] and may affect the immune-related pathogenesis of SZ and BP, is interferongamma (IFN-c). IFN-c is a pro-inflammatory cytokine mostly produced peripherally by pro-inflammatory Th1 T lymphocytes and NK cells but also centrally within the CNS by neurons and glial cells [14] . In addition to its role in microglia-mediated neuronal dysfunction [15] , IFN-c may affect the brain function by directly altering neuronal circuits [16] , synaptic plasticity [17, 18] or the kynurenine pathway [19] . Importantly, genetic variation of the IFNG gene has been associated with risk to develop SZ and BP [20] [21] [22] . However, the molecular mechanisms underlying cytokine expression involved in the pathogenesis of SZ and BP are still poorly understood. In that regard, emerging evidence supports a role for long coding RNA (lncRNAs) in the regulation of cytokines. LncRNAs are recently discovered transcriptional regulators that control the expression of genes through various mechanisms [23] . IFNG-AS1, also named NeST, lncRIfng-3 0 AS or Tmevpg1, is selectively expressed by mouse and human T lymphocytes under inflammatory Th1-polarizing conditions and is necessary for the efficient transcription of IFNG in a T-bet-dependent manner [24, 25] . IFNG-AS1 facilitates IFN-c expression through association with the WDR methyltransferases and subsequent increase in H3K4 methylation at the IFNG locus [26] . Accordingly, IFNG-AS1 lncRNA has been further associated with inflammatory and immunity-related conditions [25] , thus suggesting a potential involvement in psychiatric diseases as well. Here we aimed to evaluate the expression levels of IFNG-AS1, IFNG and IL-1Β in independent cohorts of patients with SZ and BP in comparison with healthy controls.
Materials and methods
Patients and controls. Patients clinically diagnosed SZ and BP by an expert psychiatrist were registered in this study. Table 1 recapitulates cohort description. Briefly, we selected 27 patients with SZ and 30 patients with BP based on criteria related to age (ranging between 18 and 70 years old) and positive responsiveness to medications. Also, we included 32 healthy control individuals without any inflammatory disease and any familial history of psychiatry disorder. The informed consent was obtained from all of the participants, and the investigation was performed in keeping with the Declaration of Helsinki on research with the human participant. This study was approved by the medical ethics committee of Qazvin University of medical sciences.
RNA extraction and cDNA synthesis. Five ml of blood samples was obtained from all participants in EDTA tubes and immediately processed for RNA extraction. Peripheral blood mononuclear cells (PBMCs) from patients with SZ and BP and healthy controls were isolated using FicollPaque solution gradient (lympholyte, Cedarlane, Netherlands, Sigma Chemical Co, St Louis, MO, USA). Total RNA extracted using TRIZOL Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Quality and integrity of the extracted RNAs were verified by spectrophotometry and 1% agarose gel electrophoresis and to eliminate any genomic DNA contamination samples treated with DNase I (Fermentas, Vilnius, Lithuania). Using 3 lg of purified total RNA and a 2-Steps RT-PCR (Vivantis Technologies, Selangor, Malaysia), first-strand cDNA synthesis was performed according to the manufacturer's instructions and stored in À80°C for subsequent analysis.
Gene expression analysis. Gene expression analysis was performed in duplicates using EvaGreen I master mix (Solis BioDyne, Tartu, Estonia) by the StepOne Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The relative expression of IFNG-AS1 (Forward: GACAA CATGGTACATGTGGCTAG Reverse: CCTCGGTTGCT TTGATTACACA), IFNG (Forward: ATTGGAAAGAGGA-GAGTGACAGA Reverse: TTGGACATTCAAGTCAGT-TACCG) and IL-1B (Forward: AGGGACAGGATATGGA GCAACAAG and Reverse: CATCTTTCAACACGCAGGA-CAGGT) was normalized to GAPDH (Forward: CCATGA-GAAGTATGACAAC Reverse: GAGTCCTTCCACGAT ACC), which was used as the endogenous control. The PCR program consisted of an initial denaturation step at 95°C for 15 min, followed by 40 cycles of 15 s at 95°C, 20 s at 480 IFNG-AS1, IFNG and IL-1B Expression in BP and SZ 60°C and 20s at 72°C. To verify the specificity of qPCRs, melt curve analysis and sequencing of the PCR products were performed. Statistical analysis. The Shapiro-Wilk test was used to assess whether data were normally distributed and the relative expression levels of selected genes were calculated by the DDCt method. The DCT of patient and control groups was calculated, and finally, the relative expression of genes was estimated by ratio formula (ratio = 2 ÀDDCt ) as described by Livak [27] . Independent t-test was used to analyse the statistical differences in the expression levels of selected genes, between SZ, BP and control groups. Analysing the correlations between the gene expression data and clinical features of patients was performed by Pearson's correlation and Spearman's rank tests. A Pvalue < 0.05 was considered significant. A receiver operating characteristic (ROC) curve was used to determine the selected genes cut-off values that best discriminates between SZ, BP and control groups; the area under the curve (AUC) was further used to represent an overall summary of its diagnostic accuracy. All statistical analysis was performed by GraphPad Prism 6.01 (GraphPad Software, Inc., San Diego, CA, USA).
Results

Cohort description
Samplings were performed from 30 patients with BP including 25 males and 5 females with the mean age of 39 years (ranging from 19 to 55), which 36.6% of them had a familial history of bipolar disorder. Moreover, 27 patients with SZ including 17 males and 10 females were involved in this study with the mean age of 43 years (ranging from 25 to 70) and 40.7% of them having a familial history of schizophrenia. Results were compared with a control group comprising 32 healthy individuals (26 males and 6 females) with the mean age of 31 (ranging from 16 to 46) and without any familial history of SZ and BP or other neuropsychiatric diseases. All patients were taking psychotropic treatments, antipsychotic and/or mood stabilizers with Valproate sodium and Risperidone being the most commonly used by patients with BP and SZ. Cohort characteristics are summarized in Table 1 .
Dramatic decrease in inflammatory genes expression in patients with BP and SZ
We first compared transcript levels of IL-1B, as a marker of active inflammation, in PBMCs from patients with SZ and BP and healthy controls and found that the expression level of IL-1B was significantly reduced in BP (P < 0.0001) and SZ (P < 0.0001) patients compared with controls. Moreover, no significant difference was detected in the expression level of IL-1B between patients with BP and SZ (P = 0.13) (Fig. 1A) . Evaluation of the expression levels of IFNG (P = 0.019 and P = 0.0001) and IFNG-AS1 (P < 0.0001 and P < 0.0001) in PBMCs showed significant downregulation in BP and SZ patients compared with healthy subjects. Similarly to IL-1B, there was no significant difference in IFNG (P = 0.17) or IFNG-AS1 (P = 0.76) expression between patients with BP and SZ ( Fig. 1 B-C) . The stratification of patients regarding medication (VPA versus other) did not reveal any difference in genes expression (P > 0.05) (data not shown). The ROC curve analysis showed that the expression levels of IFNG-AS1 ( Fig. 2A-B) , IFNG (Fig. 2C-D) and IL-1B (Fig. 2E-F ) genes could serve as potential biomarkers to discriminate medicated patients with BP and SZ from controls. IL-1B expression displayed the highest accuracy (AUC = 0.94 for SZ and 0.92 for BP), followed by IFNG-AS1 (AUC = 0.79 for SZ and 0.81 for BP) and IFNG (AUC = 0.78 for SZ and 0.66 for BP).
Significant correlation between the expression levels of IFNG-AS1 with IFNG genes
As previously mentioned, IFNG-AS1 lncRNA has been shown to regulated IFNG expression. We then performed Spearman's correlation coefficient tests to address the possible link between the expression levels of IFNG with its lncRNA IFNG-AS1. Results showed a strong positive correlation between the expression levels of IFNG and IFNG-AS1 both in patients with BP (P < 0.0001, r = 0.67, Fig. 3A ) and SZ (P = 0.02, r = 0.44, Fig. 3B ), and this correlation was even stronger when considering SZ + BP as a group (data not shown). Interestingly, this correlation was not statistically significant in the control group (P = 0.27, r = 0.19, Fig. 3C ). Moreover, correlation analysis with age did not yield a significant correlation of the expression levels of IL-1B, IFNG and IFNG-AS1 genes with age of BP, SZ and control individuals (P > 0.05) even when considering SZ + BP as a group (Table 2) . Jointly, these data suggest a functional correlation between the IFNG-AS1 and IFNG in the context of BP and SZ diseases and antipsychotic treatment.
Discussion
The catalog of risk genes is constantly expanding towards a polygenic model of multiple genes associating with SZ and BP risk and locating throughout the genome [28, 29] . Despite growing body of evidence of a role of immune dysfunction and infectious agents in the pathogenesis of psychiatric disorders [30] , inflammation-modifying intervention has yet not reached the pharmacological research field to develop new drugs in the treatment of patients. An imbalance in Th1/Th2 responses [31] has been suggested to participate in the pathogenesis of schizophrenia, although the relative Th1 versus Th2 contributions remain unclear.
Similarly, variation in the immune system function has been reported in patients with BP as well [32] . Consistent with this, our results implicate immunity-related genes in the pathogenesis of SZ and PB. We found decreased levels of IL-1B and IFNG in both BP and SZ patients compared with control individuals. This result is in accordance with several studies performed on blood samples from medicated patients [13, 33, 34] , although some reported increased levels of inflammatory molecules [35] . While the IL-1B release is an early event that triggers the release of other inflammatory regulators, it is considered as the 'master cytokine' of the acute phase response of the immune system [36] . Here, we show that IL-1b gene expression was lower in SZ and BP patients compared with controls. IL-1b is a well-known inflammatory molecule both in the periphery and CNS, and peripherally induced IL-1b can enter the brain by an active transport system [37] , induce its own synthesis [38] and eventually activate the hypothalamicpituitary axis (HPA) in combination with neurotransmitters such as acetylcholine and serotonin [32] . IL-1b dysregulation together HPA axis impairment is involved in SZ and BP pathogenesis [39, 40] . In addition to IL-1b, IFN-c cytokine has been implicated in various CNS pathologies through its role in cytokine induction, synaptic plasticity and neuronal development [18, 41, 42] . Moreover, a crucial role of IFN-c in psychiatric diseases is further supported by its genetic association with SZ and BP diseases [13, 20] . The observed reduced IFNG expression, as a Th1-related cytokine, in medicated patients is in line with the hypothesis of imbalance in Th1/Th2 responses as putative pathogenic processes underlying psychiatric disorders. Interestingly, a recent study from Vetlugina et al. has reported a beneficial role of the adjunctive use of IFN-c inducer for treatment of patients with schizophrenia [43] . Thus, our data together with several studies support a role of IFN-c in the pathogenesis and treatment of SZ and BP diseases and further suggest that IFN-c might exert a differential effect in a contextdependent manner.
Knowing that all patients were under antipsychotic drugs and responsive to treatment, the observed reduced levels of inflammatory genes might reflect an antiinflammatory effect of medications. Consistent with this, several studies have shown that inhibition of inflammation may contribute to the therapeutic effects of psychotropic drugs [44, 45] . However, the mechanism underlying the anti-inflammatory properties of psychotropic drugs is not fully understood. Due to ethical limitations, immunebased therapies can be evaluated only as add-on therapies in psychiatry, mostly in treatment-resistant patients. Our data together with previous evidence of the role of immune system in psychiatric disorders further highlight the need to evaluate the potential of immune-based approaches in the treatment of patients with SZ and BP.
Additionally, we found downregulation of IFNG-AS1 long non-coding RNA in patients with SZ and BP versus controls. IFNG-AS1 lncRNA has recently emerged as an enhancer of inflammation, promoting Th1 responses in immune diseases [46] [47] [48] . These data suggest that IFNG-AS1 might contribute to the inflammatory component in the pathogenesis of patients with SZ and BP, possibly through the aforementioned mechanisms involving ............................................................................................................................................................... WDR5 molecule of the histone methyltransferase complex and histone 3 methylation at the IFN-c locus [26] . Moreover, we found a strong positive correlation between IFNG-AS1 with IFNG expression in patients with BP and SZ, which is in accordance with the previous report of coregulation of IFNG and its related lncRNA IFNG-AS1 [48] . Surprisingly, this correlation could not be observed in the control group. A plausible explanation relies on the potential anti-inflammatory impact of psychotropic agents on lncRNAs that control the expression of target genes such as IFNG. This further reveals a potential role of IFNG-AS1 lncRNA in the regulation of the Th1/Th2 balance during pathogenic processes as well as therapeutic effects in psychiatric disorders. An additional interpretation would be that, similarly to other antisense lncRNAs which regulate the expression of coding genes at the transcriptional level, IFNG-AS1 expression could reflect the intend to control the aberrant expression level of the IFNG in both patient groups of SZ and BP. Finally, some studies have shown changes in the expression of proapoptotic genes in bipolar disorder and schizophrenia [3, 49] . Given that IFNG can also trigger cell death and apoptosis [50] , these findings jointly suggest a putative involvement of apoptosis in the observed IFNG-AS1 transcriptional changes, which requires further studies. Moreover, the area under the ROC curve implies that expression level of these three genes in the PBMCs may serve as biomarkers to monitor the therapeutic effect of psychotropic drugs in patients with SZ and BP. Further prospective studies are necessary to address the potential of these cut-off values to distinguish patients with SZ and/or BP from healthy controls in combination with other existing biomarkers. Given that SZ and BP are clinically distinct pathologies with possibly shared inflammatory component, IFNG-AS1 lncRNA quantification might reveal itself useful to assess the Th1/Th2 imbalance in psychiatric diseases in general.
Finally, our findings must be considered in view of the small sample size used in this analysis. Therefore, studies with larger sample size are required in order to clarify the role of the immune variables in psychiatric diseases such as SZ and BP and to further unravel the effect of antipsychotic drugs in the immune-related genes and their regulators, lncRNAs in particular. In conclusion, our results reveal a drastic downregulation of immunity-related genes in medicated patients with SZ and BP at the intracellular level. These findings shed further light on the putative role of IFNG-AS1 lncRNA in the pathogenesis of the SZ and BP disorders, which needs to be further explored.
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